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Abstract 
Introduction and objectives. Our aim was to assess the prognostic value of the INTERMACS (Interagency Registry 
for Mechanically Assisted Circulatory Support) scale in patients undergoing urgent heart transplantation (HT). 
Methods. Retrospective analysis of 111 patients treated with urgent HT at our institution from April, 1991 to October, 
2009. Patients were retrospectively assigned to three levels of the INTERMACS scale according to their clinical 
status before HT. 
Results. Patients at the INTERMACS 1 level (n = 31) more frequently had ischemic heart disease (p = 0.03) and post-
cardiothomy shock (p = 0.02) than patients at the INTERMACS 2 (n = 55) and INTERMACS 3-4 (n = 25) levels. 
Patients at the INTERMACS 1 level showed higher preoperative catecolamin doses (p = 0.001), a higher frequency 
of use of mechanical ventilation (p < 0.001), intraaortic balloon (p = 0.002) and ventricular assist devices (p = 0.002), 
and a higher frequency of preoperative infection (p = 0.015). The INTERMACS 1 group also presented higher central 
venous pressure (p = 0.02), AST (p = 0.002), ALT (p = 0.006) and serum creatinine (p < 0.001), and lower 
hemoglobin (p = 0.008) and creatinine clearance (p = 0.001). After HT, patients at the INTERMACS 1 level had a 
higher incidence of primary graft failure (p = 0.03) and postoperative need for renal replacement therapy (p = 0.004), 
and their long-term survival was lower than patients at the INTERMACS 2 (log rank 5.1, p = 0.023; HR 3.1, IC 95% 
1.1-8.8) and INTERMACS 3-4 level (log rank 6.1, p = 0.013; HR 6.8, IC 95% 1.2-39.1). 
Conclusions. Our results suggest that the INTERMACS scale may be a useful tool to stratify postoperative prognosis 
after urgent HT. 
Resumen 
Introducción y objetivos. Analizar el valor pronóstico de la escala INTERMACS (Interagency Registry for 
Mechanically Assisted Circulatory Support) en pacientes tratados con trasplante cardiaco urgente. 
Métodos. Análisis retrospectivo de 111 pacientes tratados con trasplante cardiaco urgente en nuestro centro entre abril 
de 1991 y octubre de 2009. Se asignó retrospectivamente a los pacientes a tres niveles de la escala INTERMACS en 
función de su situación clínica previa al trasplante cardiaco. 
Resultados. Los pacientes del grupo INTERMACS 1 (n = 31) presentaban mayor frecuencia de cardiopatía isquémica 
(p = 0,03) y shock tras cardiotomía (p = 0,02) que los pacientes del grupo INTERMACS 2 (n = 55) y los pacientes del 
grupo INTERMACS 3-4 (n = 25), así como mayores dosis de catecolaminas (p = 0,001), mayor empleo de 
ventilación mecánica (p < 0,001), balón de contrapulsación (p = 0,002) y dispositivos de asistencia ventricular 
(p = 0,002) y mayores tasas de infección preoperatoria (p = 0,015). El grupo INTERMACS 1 también mostraba 
mayores cifras de presión venosa central (p = 0,02), GOT (p = 0,002), GPT (p = 0,006) y creatinina (p < 0,001) y 
menores cifras de hemoglobina (p = 0,008) y aclaramiento de creatinina (p = 0,001). Tras el trasplante cardiaco, los 
pacientes del grupo INTERMACS 1 presentaron mayores incidencias de fracaso primario del injerto (p = 0,03) y 
necesidad de terapia de sustitución renal (p = 0,004), y su supervivencia a largo plazo fue menor que la de los 
pacientes de los grupos INTERMACS 2 (log rank = 5,1; p = 0,023; razón de riesgos [HR] = 3,1; intervalo de 
confianza [IC] del 95%, 1,4-6,8) e INTERMACS 3-4 (log rank = 6,1; p = 0,013; HR = 4; IC del 95%, 1,3-12,3). 
Conclusiones. Nuestros resultados indican que la escala INTERMACS resulta útil para estratificar el pronóstico 
postoperatorio tras el trasplante cardiaco urgente. 
Abbreviations. HF, heart failure; INTERMACS, Interagency Registry for Mechanically Assisted Circulatory 
Support; HT, heart transplantation; NTO, National Transplant Organization 
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Introduction 
Heart transplantation (HT) improves survival and patient quality of life in select cases of advanced heart 
diseases that have no possibility of responding to other treatments.1 Given that the prognosis for 
candidates for this type of treatment can be poor due to the time spent waiting for the organ, the National 
Transplant Organization (NTO) reserves the possibility of granting urgent priority status on the HT 
waiting list for those patients with a high predicted short-term mortality in the absence of HT. 
In Spain, the growing shortage in recent years of optimum donors has led to a progressive increase in 
HT performed as an urgent procedure, in spite of a postoperative mortality rate that is significantly higher 
than in elective HT.2 The current NTO criteria for including patients on the waiting list for urgent HT 
establishes a series of levels of priority based solely on the need for various types of life support.3 This 
means that there is a very heterogeneous mix of patients in each priority level with regard to clinical 
situation, hemodynamic deterioration, and extent of target organ damage. Under these conditions, the 
current classification does not constitute an optimal tool for making treatment decisions, comparing 
results between levels or predicting survival following HT. 
The INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support) scale helps 
to assign patients with advanced heart failure (HF) into seven levels according to hemodynamic profile 
and level of target organ damage (Table 1).4 This classification was defined in the context of a multi-
center registry of ventricular assist devices4 and 5 with the objective of unifying criteria to describe the 
clinical state of advanced HF patients, optimizing perioperative risk prediction and clarifying the 
instructions for each of the available alternative treatments. The INTERMACS scale has demonstrated its 
significance in predicting mortality4 and 5 and postoperative complications6 following the implantation of 
ventricular assist devices, but as of yet its prognostic value in the context of HT has not been established. 
The objective of this study is to analyze the usefulness of the INTERMACS scale for stratifying 
postoperative prognoses in patients with advanced HF receiving urgent HT. 
Table 1. INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support) Scale for Classifying Patients With 
Advanced Heart Failure. 
Profiles Definition Description 
   
INTERMACS 1 “Crash and burn” 
Hemodynamic instability in spite of increasing doses of catecholamines and/or 
mechanical circulatory support with critical hypoperfusion of target organs (severe 
cardiogenic shock) 
INTERMACS 2 
“Sliding on 
inotropes” 
Intravenous inotropic support with acceptable blood pressure but rapid deterioration 
of kidney function, nutritional state, or signs of congestion 
INTERMACS 3 “Dependent stability” 
Hemodynamic stability with low or intermediate, but necessary due to hypotension, 
doses of inotropics, worsening of symptoms, or progressive kidney failure 
INTERMACS 4 “Frequent flyer” 
Temporary cessation of inotropic treatment is possible, but the patient presents 
frequent symptom recurrences and typically with fluid overload 
INTERMACS 5 “Housebound” 
Complete cessation of physical activity, stable at rest, but frequently with moderate 
water retention and some level of kidney dysfunction 
INTERMACS 6 “Walking wounded” 
Minor limitation on physical activity and absence of congestion while at rest. Easily 
fatigued by light activity 
INTERMACS 7 “Placeholder” 
Patient in NYHA functional class II or III with no current or recent unstable water 
balance 
   
 
NYHA, New York Heart Association. 
  
Methods 
Study Population 
We performed a retrospective analysis of the historical cohort of adult patients treated by an urgent HT at 
our hospital between April 1991 and October 2009. We included all patients in which urgent HT was 
indicated due to heart disease with advanced HF and hemodynamic instability and who were dependent 
on vasoactive amines and/or mechanical circulatory support devices or presented malignant ventricular 
arrhythmias which were recurrent and refractory to conventional treatment. In all cases a 
multidisciplinary team of cardiologists, cardiac surgeons and intensivists decided whether to include a 
patient on the waiting list for urgent HT according to the criteria established by the NTO for each period 
during the study. 
Our protocol until 2001 recommended induction immunosuppressive treatment with OKT-3 
antibodies during the first 7 days following HT. Since that time, our team has used induction therapy with 
basiliximab at days 0 and 4 post-HT. Except for cases with contraindications, all patients received triple 
immunosuppressive therapy with prednisone, a cell proliferation inhibitor (mycophenolate mofetil or 
azathioprine) and an anticalcineurinic drug (tacrolimus or cyclosporine) or an mTOR (mammalian target 
of rapamycin) inhibitor (everolimus or sirolimus). 
Data Collection 
The information for the study was obtained by performing individualized reviews of patient medical 
histories. Patients were informed as to the intent of the study, and each provided their verbal consent in 
front of witnesses to participate in the analysis of their clinical information. We designed a data collection 
form which included epidemiological, clinical, treatment, and complementary donor/recipient test 
variables, as well as those relating to the surgical procedure itself. We defined the following adverse 
events that could occur during the postoperative hospitalization period after an HT: 
 
– Postoperative death: death due to any cause during the postoperative hospitalization period. 
– Major bleeding: bleeding that requires a transfusion of 4 or more units of packed red blood cells 
and/or causes hemodynamic instability requiring inotropic infusion and/or surgical reintervention. 
– Surgical reintervention: cardiac surgery for any reason. 
– Renal replacement therapy: need for conventional hemodialysis and/or continuous veno-venous 
hemodiafiltration. 
– Primary graft failure: left ventricle or biventricular systolic dysfunction of the heart graft 
accompanied by hemodynamic instability, requiring mechanical circulatory support and/or infusion of 
vasoactive drugs. 
– Acute right ventricular failure: isolated systolic dysfunction of the right ventricle in the heart graft 
accompanied by hemodynamic instability, requiring mechanical circulatory support and/or infusion of 
vasoactive drugs. 
– Acute rejection: Grade 2R or greater acute cellular rejection on the International Society for Heart and 
Lung Transplantation scale, acute cellular rejection grade <2R with hemodynamic compromise, 
empirical treatment for a suspected acute cellular rejection unproven by biopsy, or a humoral rejection 
defined as graft dysfunction unexplained by other causes associated with the detection of C4d deposits 
with a pericapillary pattern in the endomyocardial biopsy using immunofluorescence. 
– Infection: any infection as demonstrated using cultures and/or the need for empirical antibiotic 
treatment due to the suspicion of an infection. For patients that presented infections during 
hospitalization before the urgent HT, this event was considered only when new infectious agents were 
isolated in microbiological studies or the antibiotic regimen administered was changed due to 
suspicion of a new infection. 
 
The information from long-term follow-ups was obtained from the prospective registry at the Heart 
Transplantation Unit at our center. The authors had reliable data on the vital status of all patients on 19 
November 2009. 
  
INTERMACS Profiles 
The INTERMACS level for each patient immediately before urgent HT surgery was assigned 
retrospectively and independently by two cardiologists (EBC, MCL) after a detailed revision of their 
clinical histories. Any discrepancies in the criteria at the time were resolved by consensus. Based on the 
reduced number of patients assigned to profiles 3 and 4 and because they are frequently alternated in 
clinical practice, these were combined into one level for analysis. No patients were assigned to levels 5, 6, 
or 7. 
Statistical Analysis 
Categorical variables were presented as absolute frequencies (percentages) and continuous variables were 
presented as standard deviation of the mean (SD). We used the χ2 test for comparing categorical variables 
and an analysis of variance (ANOVA) test for continuous variables. The Scheffé test was used for a 
posteriori comparison between pairs in the cases where variables showed a statistically significant 
difference in the ANOVA results. Survival curves were constructed using the Kaplan-Meier method, and 
compared using a log rank test. Lastly, we constructed a multivariate Cox proportional hazards model 
with forced inclusion of variables independently associated with survival following HT in our sample 
(year of HT, diabetes mellitus, age of recipient, sex of recipient) and other variables that, based on 
existing literature, clinical experience, and/or asymmetrical distribution between the levels, were 
considered to be potential confounding factors (type of heart disease, previous heart surgery, duration of 
ischemia, donor age, donor sex, vasoactive support of the donor). All analyses were performed using 
SPSS version 13.0. The significance level was set at P < .05. 
Results 
Study Population 
Between April 1999 and October 2009, 112 patients received an urgent HT in our hospital. All complied 
with the inclusion criteria for the study, except for one patient in which the suggestion for an urgent HT 
had been motivated by an aortic pathology that was not susceptible to surgical repair. This patient was 
excluded. Therefore, the study population consisted of 111 patients (18 women) with a mean age of 
50.2 ± 12.9 years. The INTERMACS level 1 group included 31 patients (27.9%), with a mean age of 
50.9 ± 10.3 years and 3 women (9.7%). The INTERMACS level 2 group included 55 patients (49.6%) 
with a mean age of 51.1 ± 12.6 years and 8 women (14.5%). Lastly, the INTERMACS level 3-4 group 
consisted of 25 patients (22.5%) with a mean age of 48.9 ± 16.2 years and 7 women (28%). 
Preoperative Clinical Characteristics 
Table 2 shows the preoperative clinical characteristics of the study patients. The patients in INTERMACS 
level 1 had a greater frequency of ischemic heart disease (P = .03) and postcardiotomy shock (P = .02) 
than patients in levels 2 and 3-4, but the proportion of patients with a New York Heart Association 
(NYHA) functional class of III-IV before hospitalization which was the principal reason for the urgent 
HT was significantly higher in the INTERMACS 3-4 group (P < .001). Patients in INTERMACS level 1 
required larger doses of vasoactive amines and more frequently received support in the form of 
mechanical ventilation, balloon counterpulsation, or ventricular assist devices. As a result, the prevalence 
of preoperative infection was greater in the INTERMACS level 1 group. 
  
Table 2. Basal Clinical Characteristics of the Study Patients Before the Urgent Heart Transplant Surgery. 
 
INTERMACS 1 
(n = 31) 
INTERMACS 2 
(n = 55) 
INTERMACS 3–4 
(n = 25) 
P 
     
Age (years) 50.9 (10.3) 51.1 (12.6) 48.9 (16.2) .77 
BMI (kg/m2) 25.2 (3.0) 25.5 (4.6) 25.1 (3.5) .91 
Female 3 (9.7%) 8 (14.5%) 7 (28.0%) .16 
Basal NYHA class III-IV a 9 (29.0%) 32 (58.2%) 22 (88.0%) <.001 
Previous inclusion on the ordinary priority 
donor waiting list 
7 (22.6%) 18 (32.7%) 18 (72.0%) <.001 
Heart Disease    .03 
 Ischemic heart disease 21 (67.7%) 28 (50.9%) 7 (28.0%)  
 Dilated myocardiopathy 6 (19.4%) 18 (32.7%) 15 (60.0%)  
 Other 4 (12.9%) 9 (16.4%) 3 (12.0%)  
Post-cardiotomy shock 5 (16.1%) 2 (3.6%) 0 (0.0%) .02 
Arterial hypertension 12 (38.7%) 15 (27.3%) 7 (28.0%) .52 
Hypercholesterolemia 13 (41.9%) 16 (29.1%) 5 (20.0%) .20 
Diabetes mellitus 9 (29.0%) 6 (10.9%) 6 (24.0%) .09 
Tobacco use 10 (32.3%) 25 (45.5%) 6 (24.0%) .15 
Previous heart surgery 7 (22.6%) 17 (30.9%) 6 (24.0%) .65 
Auricular fibrillation 7 (22.6%) 18 (32.7%) 11 (44.0%) .23 
Ventricular arrhythmia 15 (48.4%) 17 (30.9%) 13 (52.0%) .12 
Cardiopulmonary arrest b 10 (32.3%) 13 (23.6%) 10 (40.0%) .31 
Preoperative infection c 16 (51.6%) 20 (36.4%) 5 (20.0%) .015 
ICD 3 (9.7%) 8 (14.5%) 4 (12.0%) .80 
CRT 1 (3.2%) 3 (5.5%) 2 (8.0%) .73 
Anticoagulation treatment 18 (58.2%) 39 (70.9%) 16 (64.0%) .47 
 Heparin 14 (45.2%) 34 (61.8%) 10 (40.0%)  
 Oral anticoagulants 4 (13.0%) 5 (9.1%) 6 (24.0%)  
Antiaggregation 14 (45.2%) 25 (44.4%) 6 (24.0%) .32 
 Aspirin 11 (35.5%) 25 (37.1%) 6 (24.0%)  
 Aspirin + clopidogrel 3 (9.7%) 4 (7.3%) 0 (0.0%)  
Catecholamines 31 (100.0%) 55 (100.0%) 20 (80.0%) <.001 
 Inotropic indexd 87.1 (86.1) 22.3 (12.1) 6.3 (4.7) <.001 
Counterpulsation balloon 27 (87.1%) 39 (70.9%) 11 (44.0%) .002 
Ventricular assist 8 (25.8%) 3 (5.5%) 0 (0.0%) .002 
 Extracorporeal 7 (22.6%) 2 (3.6%) 0 (0.0%)  
 Percutaneous 1 (3.2%) 1 (1.9%) 0 (0.0%)  
Invasive mechanical ventilation 26 (83.9%) 28 (50.9%) 6 (24.0%) <.001 
Renal replacement therapy e 3 (9.7%) 1 (1.9%) 0 (0.0%) .09 
     
 
BMI, body mass index; CRT, cardiac resynchronization therapy; ICD, Implantable cardioverter defibrillator; NYHA, New York 
Heart Association; SD, standard deviation. 
Data express mean (standard deviation or n (%)). 
a Functional class of the patient one month before the hospitalization event that brought about the inclusion on the urgent heart 
transplant list. 
b Episode of ventricular fibrillation, ventricular tachycardia with no pulse, asystole, or electromechanical dissociation. 
c Clinical suspicion of infection and isolation of the causative microbe or need for empirical antibiotic treatment before surgery and 
during the hospitalization period that coincided with the inclusion on the waiting list for an urgent heart transplant. 
d Wernovsky inotropic index: dobutamine dose + dopamine dose + adrenaline dose × 100 + noradrenaline dose × 100 + milrinone 
dose × 15 μg / kg / min. Adapted from Wernovsky et al. A comparison of low-flow cardiopulmonary bypass and circulatory arrest. 
Circulation. 1995;92:2226–35. 
e Conventional hemodialysis or continuous veno-venous hemodiafiltration. 
Preoperative Hemodynamic Status 
Preoperative hemodynamic parameters are summarized in Table 3. The three INTERMACS levels 
differed only in central venous pressure (P = .02), which was significantly higher in level 1 patients 
(17.8 ± 3.1 mm Hg) than in level 2 patients (10.4 ± 5.5 mm Hg; p = .03) and level 3-4 patients 
(9.8 ± 6.3 mm Hg; p = .04). 
  
Table 3. Hemodynamic Situation of Study Patients Before the Urgent Heart Transplantation. 
 
INTERMACS 1 
(n = 31) 
INTERMACS 2 
(n = 55) 
INTERMACS 3–4 
(n = 25) 
P 
     
Cardiac output (L/min) 3.3 (0.5) 3.7 (0.9) 3.6 (0.7) .22 
Cardiac index (L/min/m2) 1.8 (0.3) 2.1 (0.5) 2.0 (0.4) .25 
Systolic PA pressure (mm Hg) 51.3 (15.0) 50.4 (13.6) 49.4 (13.6) .91 
Mean PA pressure (mm Hg) 38.1 (12.7) 34.7 (8.9) 33.0 (9.1) .15 
Pulmonary capillary pressure (mm 
Hg) 
26.9 (10.0) 24.5 (7.7) 24.9 (7.3) .64 
Transpulmonary gradient (mm Hg) 12.9 (8.1) 11.4 (4.9) 7.8 (5.0) .07 
Pulmonary vascular resistance (WU) 3.7 (2.2) 2.8 (1.7) 2.5 (1.9) .10 
Total pulmonary resistance (WU) 12.0 (4.5) 9.9 (3.6) 9.8 (3.4) .25 
Central venous pressure (mm Hg) 17.8 (3.1) 10.4 (5.5) 9.8 (6.3) .02 
LVEF (%) 0.21 (0.6) 0.23 (0.7) 0.19 (0.7) .09 
     
 
PA, pulmonary artery; WU, Wood units; LVEF, left ventricular ejection fraction. 
Data express mean (standard deviation). 
Preoperative Laboratory Parameters 
The INTERMACS level 3-4 patients presented significantly higher hemoglobin and hematocrit levels 
than patients in levels 1 and 2 (Table 4). INTERMACS level 1 patients presented significantly higher 
levels of glutamate-oxalate transaminase, glutamate-pyruvate transaminase, and lactate dehydrogenase, as 
well as higher plasma creatinine levels and a lower creatinine clearance than in patients from 
INTERMACS levels 2 and 3-4. 
Table 4. Laboratory Results for Study Patients Before the Urgent Heart Transplantation. 
 
INTERMACS 1 (n = 31) INTERMACS 2 (n = 55) INTERMACS 3-4 (n = 25) P 
     
Hemoglobin (g/dL) 10.8 (2.4) 11.3 (2.3) 12.7 (1.7) .008 
Hematocrit (%) 31.6 (6.9) 34.1 (6.8) 37.9 (5.1) .004 
Total bilirubin (mg/dL) 2.2 (2.1) 1.8 (1.7) 2.4 (1.7) .45 
GOT (UI / L) 1337 (1993) 317 (1011) 165 (297) .002 
GPT (UI / L) 1220 (2403) 205 (403) 238 (558) .006 
GGT (UI / L) 238 (487) 141 (172) 93 (66) .20 
LDH (UI / L) 2494 (1968) 1209 (1822) 806 (550) .002 
Creatinine (mg/dL) 2.3 (1.2) 1.4 (0.5) 1.3 (0.5) <.001 
Creatinine clearance (mL/min/m2)* 49.1 (25.4) 74.3 (31.8) 77.7 (37.2) 0.001 
     
 
GGT, gamma-glutamil transpeptidase; GOT, glutamate-oxalacetate transpeptidase; GPT, glutamate-pyruvate transpeptidase; LDH, 
lactate dehydrogenase; SD, standard deviation. 
Data express mean (standard deviation). 
* Calculated with the Cockoft-Gault formula: [(140-age) × weight (in Kg) / (72 x plasma creatinine) (mg/dL)] × 0.85 (in women). 
Heart Transplant 
As displayed in Table 5, the three study groups did not differ significantly in time on the waiting list for 
urgent HT, the duration of ischemia, or the sex or age of the donors. However, the use of donors that had 
required vasoactive amines was higher in INTERMACS level 1 patients (P = .047). The time spent on 
extracorporeal circulation was slightly higher in INTERMACS level 1 patients, although this difference 
was not significant (P = .06) 
  
Table 5. Characteristics of the Urgent Heart Transplant (HT) Surgery in Study Patients. 
 
INTERMACS 1 
(n = 31) 
INTERMACS 2 
(n = 55) 
INTERMACS 3–4 
(n = 25) 
P 
     
Time spent on the urgent HT waiting list 
(days) 
3.1 (2.3) 3.0 (2.4) 3.1 (2.5) .96 
Biatrial technique 2 (6.5%) 3 (5.5%) 2 (8.0%) .90 
Donor age (years) 36.8 (13.6) 34.9 (13.8) 37.4 (13.0) .70 
Female donor 7 (22.6) 15 (27.3) 6 (24.0) .88 
Donor on vasoactive drugs 24 (77.4%) 36 (65.5%) 13 (52.0%) .047 
CPR donor 0 (0.0%) 3 (5.5%) 1 (4.0%) .42 
Duration of ischemia (min) 213.2 (76.6) 192.4 (78.0) 218.0 (82.6) .31 
Time on ECC (min) 143.4 (80.2) 126.9 (33.7) 116.8 (24.1) .06 
Use of nitrous oxide 9 (29.0%) 18 (32.7%) 9 (36.0%) .86 
     
 
BMI, body mass index; CPR, cardiopulmonary resuscitation; ECC, extracorporeal circulation. 
Data express mean (standard deviation) or n (%). 
Postoperative Complications 
The incidence of complications during the postoperative hospitalization period is shown in Figure 1. The 
incidence of primary graft failures was 35.8% in INTERMACS level 1 patients, 18.0% in level 2, and 
12.0% in level 3-4 (P = .03). Renal replacement therapy was required in 48.4% of patients in 
INTERMACS level 1, 16.4% in level 2, and 20.0% in level 3 (P = .004). The incidence of postoperative 
infections was 51.6% in INTERMACS level 1, 47.3% in level 2, and 28.0% in levels 3, but this 
difference was not significant (P = .09). The most frequent postoperative infections were respiratory 
infections (9 patients in INTERMACS level 1, 12 patients in level 2, and 4 patients in level 3-4), 
bacteraemia (7 patients in level 1, 5 patients in level 2, and 2 patients in level 3-4), and urinary tract 
infections (1 patient in level 1 and 3 patients in level 2). During the postoperative period, no statistically 
significant differences were observed between the three levels in the incidence of isolated right 
ventricular failure, major bleeding, surgical reoperation, or acute rejection. The intrahospital mortality 
rate following HT was significantly higher (P < .001) in INTERMACS level 1 patients (45.2%) than in 
level 2 patients (16.4%) and level 3-4 patients (8.0%). 
 
 
 
Figure 1. Incidence of postoperative complications in patients included in the study. IRVF, isolated right ventricular failure; PGF, 
primary graft failure; RRT, renal replacement therapy; SR, surgical reoperation.  
Post-transplantation Survival 
After a mean follow-up of 4.5 ± 4.3 years (maximum: 14.9 years), we observed a statistically significant 
difference between post-HT survival curves for the three study groups (log rank 8.4, P = .015; Fig. 2A). 
The crude and adjusted patient mortality for INTERMACS level 1 patients was significantly higher than 
in INTERMACS level 2 patients (log rank 5.1, P = .023; HR 3.1, 95% CI 1.4-6.8) and in INTERMACS 
level 3-4 patients (log rank 6.1, P = .013; HR 4.0, 95% CI 1.3-12.3). We observed no significant 
differences with regard to crude or adjusted patient mortality between the INTERMACS groups 2 and 3-4 
(log rank 0.79, P = .37 HR 1.3, 95% CI 0.4-4.0). The greater mortality observed in the INTERMACS 
level 1 patients was concentrated in the first year post-HT (log rank 14.3, P = .01; Figure 2B). We 
observed no significant differences between groups with regard to the long-term prognosis of patients that 
survived the first year post-transplantation (log rank 0.83, P = .66; Fig. 2C). Table 6 outlines the causes of 
death. 
 
 
 
Figure 2. Survival following heart transplantation in patients included in the study. A. Long-term follow-up. B. Follow-up during 
the first year after the transplant. C. Long-term follow-up of patients that survived the first year after the transplant. 
  
Table 6. Cause of Death in Study Patients According to INTERMACS Level Before the Urgent Heart Transplant. 
Level Causes of death < 1 year postrasplant Causes of death >1 year postrasplant 
   
INTERMACS 1 (n = 31) Multi-system failure (n = 6) Acute rejection (n = 1) 
 Primary graft failure (n = 5) Graft coronariopathy (n = 1) 
 Infection (n = 2)  
 Other (n = 2)  
INTERMACS 2 (n = 55) Primary graft failure (n = 4) Neoplasm (n = 9) 
 Multi-system failure (n = 2) Infection (n = 2) 
 Infection (n = 2) Graft coronariopathy (n = 1) 
 Other (n = 1)  
INTERMACS 3 (n = 218) Infection (n = 2) Infection (n = 1) 
 Multi-system failure (n = 1) Other (n = 2) 
   
 
Discussion 
The results from our study suggest that the INTERMACS scale is a useful tool for stratifying 
postoperative prognoses in patients with advanced HF who receive urgent HT. Following an adjustment 
for potential confounding factors, post-HT mortality of patients that were preoperatively in INTERMACS 
level 1 (severe cardiogenic shock) was three times greater than in patients in INTERMACS level 2 (rapid 
clinical deterioration in spite of inotropics) and about four times greater than in patients in INTERMACS 
level 3-4 (stable NYHA IV with or without inotropics). This result was mainly due to increased mortality 
as a result of multiorgan failure and primary graft failure during the immediate postoperative period, with 
no significant differences between groups with respect to long-term survival of patients that survived the 
first year following HT. Our study showed no significant differences in survival following HT between 
patients with preoperative placement in INTERMACS level 2 and 3-4. 
The main strength that explains the prognostic value of the INTERMACS classification system in 
patients treated by urgent HT lies in its ability to stratify precisely the clinical and hemodynamic situation 
of the recipient before the surgical procedure. In this study, the patients that arrived at the HT in 
INTERMACS level 1 presented a more severe level of hemodynamic deterioration than those in 
INTERMACS levels 2 and 3-4. They also required preoperative mechanical circulatory support and 
greater doses of vasoactive amines more frequently. Patients in INTERMACS level 1 also presented more 
severe dysfunction of target organs. This was reflected in a greater need for invasive ventilatory support 
and lower analytical parameters of liver and kidney function. In our study, the typical clinical profile of a 
patient in INTERMACS 1 was that of an individual with ischemic heart disease, good previous functional 
class or even no previous history of heart failure, presenting an acute coronary event that evolves rapidly 
into severe cardiogenic shock with severe target organ damage in spite of high doses of vasoactive drugs 
and mechanical circulatory support. A patient in INTERMACS level 3-4 typically has a known idiopathic 
dilated myocardiopathy and a history of advanced heart failure, in the majority of cases is already on the 
elective HT waitlist, presents an episode of decompensation with preservation of target organ function, 
and requires a lower level of hemodynamic support. The profile of INTERMACS level 2 patients 
represents an intermediate clinical situation between the two extremes. This scenario is similar to that 
described in several previous studies using the INTERMACS scale to classify patients with advanced HF 
that receive a ventricular assist device.4, 5, 6 and 7 An interesting result from our study is the higher 
frequency of preoperative infection in INTERMACS level 1 patients, which we consider to be related to 
the higher frequency of using invasive devices. It should be noted that while a controlled infection may 
not be considered at the time as an absolute contraindication for HT,8 this comorbidity could seriously 
compromise the patient's postoperative evolution in some cases. 
The higher early mortality following HT in patients preoperatively in INTERMACS level 1 is mostly 
due to a high incidence of primary graft failure. This condition, which implies an extremely pessimistic 
short-term vital prognosis, has classically been considered to be related to donor factors, such as age, need 
for inotropic support, and duration of ischemia.9 In this study, we have observed no significant 
differences in age, duration of ischemia, or sex of the donors with relation to the preoperative 
INTERMACS level of the recipient. Furthermore, while the increased frequency of using donors 
dependent on vasoactive drugs in INTERMACS level 1 patients could have contributed to the high 
incidence of primary graft failure observed in this group, it does not appear to be the only cause. In recent 
years, the confirmation of positive HT results from sub-optimal donors in select recipients10 has 
contributed to focusing on the preoperative hemodynamic situation of the recipient as a determining 
factor for the risk of primary graft failure. Similarly, Segovia et al11 have observed a significant 
association between four dependent variables of the recipient (diabetes mellitus, age >60 years, need for 
inotropic support, and central venous pressure >10 mm Hg) and the risk of presenting this complication. 
The last two factors refer to a poor preoperative hemodynamic condition in the recipient, which makes 
their conclusions congruent with our observation of a high incidence of primary graft failure in patients 
that arrive at the HT in severe cardiogenic shock. INTERMACS level 1 patients also presented a greater 
need for renal replacement therapy in the postoperative period, a finding based on the poor preoperative 
kidney function and evolution of the hemodynamic situation following the surgical procedure. 
The confirmation of poor results of urgent HT in patients with an INTERMACS preoperative level 1 
status points to the need for reconsidering the clinical management of these cases. Occasionally, a 
reasonable alternative could be the implantation of a short-term ventricular assist device as a temporary 
treatment until a definitive decision on the suitability of including the patient on the waiting list for an 
urgent HT is made. Under these conditions, ventricular assist could facilitate the recuperation of target 
organ function, which could contribute to optimizing the preoperative condition of the recipient. Although 
a recent analysis showed a significant increase in postoperative mortality in patients that arrive at their 
HT with a ventricular assist device,12 other groups have obtained positive results using this 
strategy.13 and 14 In spite of the fact that rapid availability of transplant organs has historically led to a 
reduced use of ventricular assist devices in Spain,15 the growing limitations on the number of donors 
would be expected to constitute a strong impulse for this type of program in coming years. In any case, it 
is important to remember that decision-making for the treatment of patients in deep cardiogenic shock 
must ride on a careful assessment of the potential reversibility of damage to target organs: if irreversible, 
any treatment effort will probably be useless (a situation that some authors have considered 
INTERMACS level 0). It is possible, in fact, that performing urgent HT in some patients poised on the 
brink of irreversible multiorgan failure may have led to the high mortality observed in the INTERMACS 
level 1 group from our study. With an optimal distribution of donors, it would be useful to have clinical 
markers available that identify the “point of no return” in this high-risk population, for which an HT 
implies an unacceptable perioperative mortality rate and therefore should be contraindicated. Due to the 
sample size, this task is beyond the bounds of the goals of our research, but could constitute an interesting 
field of research for future multicenter studies. 
The most important limitation of our study was its retrospective design, which could have led to some 
errors in the assignment of preoperative INTERMACS levels. For a correct interpretation of the results, 
one must keep in mind the heterogeneity of the sample and the variation in selection criteria for urgent 
HT candidates throughout the years comprising the study period. Furthermore, the reduced sample size 
has not allowed us to single out statistically significant differences between groups that could be clinically 
relevant, as described in the “Discussion”. Lastly, the design of our analysis does not allow us to 
guarantee the external validity of the conclusions made. These must therefore be confirmed in future 
multicenter registries with larger sample sizes. 
Conclusions 
In spite of the aforementioned limitations, our study suggests that the INTERMACS scale can be useful to 
stratify the postoperative prognosis of patients with advanced HF that receive urgent HT. In our opinion, 
the elevated postoperative mortality rate observed in patients that arrive to their urgent HT in severe 
cardiogenic shock points to the need to rethink the treatment strategy in these cases and to stimulate the 
development of ventricular assist programs. Even if these results are not confirmed by future multicenter 
registries, the INTERMACS scale could still be a useful tool to optimize the selection of candidates for 
urgent HT and the distribution of heart donors in our field, and therefore could be incorporated in the near 
future into the habitual clinical practice of professionals in this field. 
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